Hypovolaemic phlebotomy reduced perioperative blood transfusion and improved operative conditions versus usual care in patients undergoing liver resection.

Navigating the long road of Long COVID requires more than just recovery from an infection, it demands specialized, multifaceted care to address persistent and often invisible neurological symptoms.

These 52-week data highlight bimekizumab’s efficacy in the scalp, nail, and genital region for psoriasis, along with Dermatology Life Quality Index (DLQI) improvements.

Vivek Kaul, MD, discusses how primary care providers can effectively communicate the importance of colorectal cancer screening and guide patients in selecting the most suitable option, and the significant role of patient preferences and adherence in this decision-making process, while also addressing future innovations in screening methods.

A recent study found that loneliness among adults aged 50 – 80 increased from 2018 to 2022 and dropped in 2023 and 2024.

Mayo explains current shortcomings of pruritus care in PBC and what the additions of elafibranor, seladelpar, and other agents in development may offer.

Appiah-Kubi also noted that despite elevated HbF levels, very young children with SCA already had anemia and reticulocytosis.

Pipe discussed findings from the open-label extension of the ATLAS studies at ASH 2024.

Chaturvedi discussed findings from the NeST study at ASH 2024, including an increased risk of stroke in those with silent cerebral infarction progression.

A recent study examined the phase 3 trials ADVANCE, PROGRESS, and ELEVATE and saw atogepant 60 mg as a preventive migraine treatment improves quality of life and functioning.

HepB-CpG achieved superior seroprotection response versus conventional HepB-alum in patients with HIV and nonresponse to prior hepatitis B vaccination.

Study findings highlight systemic and local autonomic imbalance in patients with IBS-C, pointing to the value of autonomic modulation in this population.

In this month's episode of Lungcast, Jacob Sands, MD, discusses the American Lung Association’s recently newly-released 2024 State of Lung Cancer report.

Panelists discuss how clinicians determine the significance of proteinuria in assessing patients for potential IgA nephropathy (IgAN), including the levels and patterns that prompt further investigation and the specific diagnostic red flags that may suggest IgAN over other kidney disorders.

Panelists discuss the role of cardiovascular risk management for patients with chronic kidney disease (CKD) and how cardiovascular care can be effectively integrated into CKD management strategies.

Panelists discuss how clinicians determine the significance of proteinuria in assessing patients for potential IgA nephropathy (IgAN), including the levels and patterns that prompt further investigation and the specific diagnostic red flags that may suggest IgAN over other kidney disorders.

A study found 66.4% of participants with probable PTSD had a life stressor of unwanted sexual experiences.

Panelists discuss the treatment options available for patients with early-stage versus advanced chronic kidney disease (CKD) and how these options should be tailored to individual patient conditions, as well as the mechanism of action of nonsteroidal mineralocorticoid receptor antagonists (MRAs) such as finerenone and their comparison to other treatment modalities.

At ASH 2024, Annette von Drygalski, MD, PharmD, described the paradigm shift that has taken place in hemophilia over the past decade.

Piatek shared the latest data update from the phase 3 ALPHA study at the ASH 2024.

Frangoul discussed highlights from the latest data update from the CLIMB SCD-121 trial of Casgevy.

Data from the PINES trial at ASH 2024 suggest eltrombopag could outperform current standard of care for platelet response in newly diagnosed pediatric ITP.

Yale study at ASH 2024 finds screening adult women for iron deficiency with a ferritin threshold of 25 µg/L is cost-effective.

A propensity score-matched study from ASH 2024 suggests GLP-1 RA use reduced VTE risk in type 2 diabetes.

While the therapy was generally well-tolerated, the PIVOT trial failed its primary endpoint of dose-limiting toxicities.